We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 88

Proposed New Regulations for PM(NOC) Proceedings
  • Bereskin & Parr LLP
  • Canada
  • July 17 2017

On July 15, 2017 the government published proposed new Regulations to change the procedure under the Patented Medicines (Notice of Compliance


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Looking into the Crystal Ball - Protecting Polymporphs to Lengthen the Drug Patent Life Cycle
  • Bereskin & Parr LLP
  • Canada, USA
  • June 7 2016

Innovative pharmaceutical companies are increasingly attempting to patent improved forms of their original drug compound. Crystalline forms of a drug


Memorandum: Case summary for Pfizer v Canada (2014 FC 1243, 2016 FCA 248)
  • Bereskin & Parr LLP
  • Canada
  • June 26 2017

The Federal Court of Appeal decision in Pfizer v. Canada (2016 FCA 248) upheld the Minister of Health’s interpretation that the 24-month stay for


Expert opinion as to what “one would expect” is speculation, not evidence
  • Bereskin & Parr LLP
  • Canada
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice


The Myriad decision: what is the impact?
  • Bereskin & Parr LLP
  • Canada
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013


Range in dosage regimen claims found not to invoke physician’s judgement
  • Bereskin & Parr LLP
  • Canada
  • April 17 2017

There has been a significant amount of uncertainty in Canada regarding the patentability of use claims which include dosages and dosage regimens


Litigation - 2016 Year in Review
  • Bereskin & Parr LLP
  • Canada
  • March 8 2017

In 2016, the Federal government proposed changes to the rules that govern litigation, the Federal Courts issued directions for the conduct of


Leave to Appeal to SCC: AstraZeneca Canada Inc et al v Apotex Inc et al (FCCA)
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

On March 10, 2016, the Supreme Court of Canada granted AstraZeneca Canada Inc.'s ("AstraZeneca") application for leave to appeal from the decision of


Supreme Court Promises to Review Contentious Patent Matter
  • Bereskin & Parr LLP
  • Canada
  • March 14 2016

At long last, the Supreme Court of Canada will hear a case involving the promise of the patent. The promise of the patent is a judge-made doctrine in